Severe Mucositis Secondary to Pembrolizumab: Report of Two Cases and Review of the Literature

The indications for use of programed cell death receptors (PD-1) inhibitors to treat cancer continues to expand rapidly. Treatment with PD-1 inhibitors has been associated with numerous immune-medicated mucocutaneous side effects. Here we report two cases of severe mucositis caused by the PD-1 inhibitor pembrolizumab and review the defining features of similar cases. Recognition of mucocutaneous toxicities of PD-1 inhibitors is increasingly important as their use continues to expand. A step wise approach to diagnosis and management is also reviewed.
Source: Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Case Report Source Type: research